** Shares of drug developer Hoth Therapeutics HOTH.O jump 96.4% to $1.61 premarket
** Co announces positive interim safety and efficacy results from a mid-stage trial testing its experimental treatment to treat skin toxicity caused due to side effects of cancer treatments
** Co was testing the treatment, HT-001, to address skin toxicities linked to a type of cancer medication called EGFR inhibitors
** Data from the study shows that 100% of patients enrolled in the trial had significant skin toxicity improvement by six weeks
** 66% of patients reported reduced pain and itching scores - HOTH
** Co says no treatment-related adverse effects have been reported
** Up to last close, stock had fallen ~47% in the past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.